WEARING A MASK IS STILL REQUIRED IN PATIENT AREAS AT SUNNYBROOK. READ OUR VISITOR GUIDELINES »

Cancer trials
Hospital  >  Care Programs  >  Odette Cancer Program  >  Clinical trials

Trial details

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

To find out more about this trial and your cancer treatment options, please speak with your doctor.

Trial short name: IMbrave152

Official title: A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Principal Investigator: Dr. Anthony Lott

Cancer type: Gastrointestinal
Cancer location: Gastrointestinal
Disease stage: Early Cancer
Trial phase: Phase 3
Intervention: Drug: Atezolizumab Drug: Bevacizumab Drug: Tiragolumab Other: Placebo

Registration #: NCT05904886

Contact e-mail: cancerclinicaltrials@sunnybrook.ca

Trial description:
Key Inclusion Criteria: • Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants • Disease that is not amenable to curative surgical and/or locoregional therapies • No prior systemic treatment for locally advanced or metastatic and/or unresectable HCC • Child-Pugh Class A • ECOG Performance Status of 0 to 1 within 7 days prior to randomization • Measurable disease according to RECIST v1.1 within 7 days prior to randomization • Adequate hematologic and end-organ function Key Exclusion Criteria: • Prior treatment with CD137 agonists or immune checkpoint blockade therapies • Treatment with investigational therapy within 28 days prior to initiation of study treatment • History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death • Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure • Treatment with systemic immunostimulatory agents • Treatment with systemic immunosuppressive medication • Active or history of autoimmune disease or immune deficiency • Untreated or incompletely treated esophageal and/or gastric varices with bleeding or that are at high risk for bleeding • A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment • Mixed histology or other subtypes/variants of HCC, including, but not limited to, known liver adenocarcinoma, fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan